文献速递血栓与止血

大型国际非重型血友病A与B队列中一步法与显色法凝血因子VIII/IX检测结果差异较小

Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
PubMed 文献 · J Thromb Haemost · 2022-12-22

研究基于国际DYNAMO队列,纳入220例凝血因子水平2至35 IU/dL的非重型血友病A和B患者,中心实验室同时用一步法和显色法检测因子VIII/IX活性。以国际血栓与止血学会科学与标准化委员会提出的比值>2.0或<0.5为主要差异标准,仅3例(1%)存在检测差异,2/175例血友病A和1/45例血友病B。

要点

  • 220例非重型血友病A和B患者中仅3例(1%)符合一步法与显色法检测差异标准。
  • 6例(3%)两种检测方法绝对差值>10 IU/dL;采用更宽松定义时超过90%(n=197)无差异结果。
  • 13例携带既往与检测差异相关突变者中仅1例存在显著检测差异。

核心结论

  • 尽管存在既往与检测差异相关的突变,观察到的检测差异仍较小,提示检测差异的存在与幅度主要由实验室变量决定。

研究设计与样本

  • 国际DYNAMO队列研究,纳入既往诊断的非重型血友病A和B且因子水平2至35 IU/dL的患者。
  • 中心实验室采用一步法和显色法测定因子VIII和IX活性水平。
  • 共纳入220例患者,其中血友病A 175例、血友病B 45例;另对13例携带既往与检测差异相关突变(文献报告≥3例)者进行亚组评估。

主要发现

  • 220例中3例(1%)符合检测差异标准,分别为血友病A 2/175例和血友病B 1/45例。
  • 6例(3%)两种检测方法结果绝对差值>10 IU/dL。
  • 采用更宽松定义时,超过90%的参与者(n=197)无差异结果。
  • 13例携带既往与检测差异相关突变者中仅1例存在显著检测差异。

关键数值与推荐

  • 主要结局采用国际血栓与止血学会科学与标准化委员会提出的相对差异定义:比值>2.0或<0.5。
  • 绝对差异定义为两种检测方法结果差值>10 IU/dL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate measurements of coagulation factor activity form an essential part of hemophilia management and are performed by the one-stage or chromogenic assay. Current literature suggests that approximately one-third of persons with nonsevere hemophilia A exhibit assay discrepancy, albeit with a high variability between studies. Such data are scarce in nonsevere hemophilia B. OBJECTIVES: To investigate the extent of factor VIII/IX one-stage and chromogenic assay discrepancy in moderate and mild hemophilia A and B. METHODS: Persons with previously diagnosed nonsevere hemophilia A and B with a factor level of 2 to 35 IU/dL were included from the international DYNAMO cohort study. Central measurements of the factor VIII and IX activity levels were performed by the one-stage and chromogenic assay. Relative and absolute discrepancy definitions were used, with the International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee proposed ratio of >2.0 or <0.5 being the primary outcome. Discrepancy was also evaluated in a subgroup of 13 persons with mutations previously associated with discrepancy (≥3 cases reported in literature). RESULTS: A total of 220 persons were included, of whom 3 (1%) showed assay discrepancy: 2/175 hemophilia A and 1/45 hemophilia B. Six persons (3%) exhibited an absolute difference >10 IU/dL between the assay results. In addition, with more lenient definitions, over 90% of participants (n = 197) had no discrepant results. Only 1 out of 13 persons with a mutation previously associated with discrepancy had significant assay discrepancy. CONCLUSION: Little assay discrepancy was observed despite the presence of mutations previously associated with discrepancy, suggesting that the presence and magnitude of assay discrepancy are largely determined by laboratory variables.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zwagemaker AF, Kloosterman FR, Gouw SC, et al. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B. J Thromb Haemost. 2022. PMID: 36696222. doi:10.1016/j.jtha.2022.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。